BrightPath Biotherapeutics Co., Ltd. (TYO:4594)

Japan flag Japan · Delayed Price · Currency is JPY
64.00
+1.00 (1.59%)
Jul 24, 2025, 3:30 PM JST
1.59%
Market Cap5.79B
Revenue (ttm)1.13M
Net Income (ttm)-1.15B
Shares Out90.49M
EPS (ttm)-14.12
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,646,700
Average Volume17,543,785
Open64.00
Previous Close63.00
Day's Range62.00 - 66.00
52-Week Range32.00 - 96.00
Beta1.28
RSI55.59
Earnings DateAug 8, 2025

About TYO:4594

BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. It is developing GRN-1201, a cancer peptide vaccine candidate that is in Phase II clinical trials for the treatment of non-small cell lung cancer, as well as in Phase I clinical trials to treat melanoma. The company is also developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 42
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4594
Full Company Profile

Financial Performance

In 2024, TYO:4594's revenue was 1.13 million, an increase of 1473.61% compared to the previous year's 72,000. Losses were -1.15 billion, -1.45% less than in 2023.

Financial Statements

News

There is no news available yet.